Kinfo
MR

Marker Therapeutics, Inc.

MRKRNASDAQHealthcare·US · USD
$1.42
+0.10 (+7.58%)
Live · 2026-06-29

Price

Key statistics

Valuation
Market cap21.93M USD
Enterprise value7.01M USD
Trailing P/E-1.80
Forward P/E-7.74
PEG ratio0.03
Price / sales6.18
Price / book1.59
Profitability
Gross margin0.00%
Operating margin-338.49%
Profit margin0.00%
Return on assets-43.59%
Return on equity-77.04%
Income (TTM)
Revenue3.55M USD
Gross profit-7.96M USD
EBITDA0.00 USD
Net income-10.90M USD
Diluted EPS-$0.55
Rev. growth (YoY)0.00%
Balance sheet
Total cash14.92M USD
Total debt0.00 USD
Debt / equity0.00
Current ratio4.79
Book value / share$0.83
Cash flow (TTM)
Operating cash flow-7.92M USD
Levered free cash flow-5.25M USD
Shares & price
Shares outstanding16.67M
Float13.81M
Held by institutions23.40%
Beta1.45
50-day MA$1.44
200-day MA$1.35
52-week high$4.07
52-week low$0.81
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-06-020.230.17−26.09%2026-05-15-0.19-0.16+15.79%2026-03-18-0.19-0.04+78.95%2025-11-13-0.21-0.12+42.86%
About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapeutic solutions in the pharmaceuticals and biotech sector. Headquartered in Houston, Texas, and founded in 1999, the company specializes in advancing treatments designed to address significant unmet medical needs. Marker Therapeutics operates within the competitive biotechnology industry, where it engages in research, development, and commercialization of therapeutic products. The company's work spans clinical and preclinical stages, targeting disease areas where novel biological approaches can provide meaningful patient benefits. As a publicly traded biotechnology firm, Marker Therapeutics is subject to the rigorous regulatory and scientific standards that govern drug development and approval. The company maintains operations focused on translating scientific discoveries into effective treatments, contributing to the broader landscape of modern therapeutic innovation and advancing healthcare solutions.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Juan F. Vera M.D.
Employees
5
Headquarters
Houston, TX, United States

Frequently asked questions about Marker Therapeutics, Inc.